Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa for Ovarian Stimulation in Donors
Overview
- Phase
- Not Applicable
- Intervention
- Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa
- Conditions
- Controlled Ovaria Stimulation
- Sponsor
- Institut Universitari Dexeus
- Enrollment
- 40
- Primary Endpoint
- Total dose of gonadotrophins
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
Currently, controlled ovarian stimulation (COS) in oocyte donors is performed by daily injections of gonadotropins( recombinant FSH) plus a GnRH Antagonist usually form 5th-6th stimulation day until ovulation induction with a bolus of another injection of a gonadotropin-releasing hormone (GnRH) Agonist. Injections of the GnRH Antagonist avoid untimely luteinizing hormone (LH) surge and spontaneous ovulation prior to follicular aspiration. There is a preparation of long-acting recombinant follicle stimulating hormone (rFSH= (corifollitropin alfa (FSH-CTP), Elonva®, MSD), that allows that a single subcutaneous injection substitutes the first 7 days of daily gonadotropin injections. On the other hand, a contraceptive oral progesterone only( Desogestrel, DSG) is available for contraception, avoiding the LH surge.
In donors, by administering a single injection of FSH-CTP and oral desogestrel since the first menstruation day, the total number of injections administered is reduced and less discomfort is experienced without adverse impact on ovarian response.
Other authors have reported good results using similar synthetic progestins (Medroxyprogesterone, dihydrogesterone, and natural progesterone).
No description of the hormonal and ovarian response under this protocol has been published. Direct comparison between this novel protocol and the classical GnRH- antagonist plus daily gonadotropins has not been reported.
Investigators
Dr. Francisca Martínez
MD PhD
Institut Universitari Dexeus
Eligibility Criteria
Inclusion Criteria
- •Fulfilling inclusión medical and legal criteria (RD - Spanish law adapting european rule-9/2014)
- •Who had had undergone previously convencional COS (controlled ovarian stimulation) with FSH-CTP and daily antagonist injections
- •Given signed consent form.
Exclusion Criteria
- •Previous low response to COS
- •Previous ovarian hyperstimulation syndrome.
- •Ovarian cysts.
Arms & Interventions
DSG-CTP
Intervention: Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa
Outcomes
Primary Outcomes
Total dose of gonadotrophins
Time Frame: At the end of stimulation treatment period (from day of corifollitropin administration until the day of triggering) ) an average 10 days after beginning treatment
Sum of gonadotrophins dose
Oocyte retrieved
Time Frame: Oocyte retrieval day an average 10 days after beginning treatment
Number of oocyte retrieved